Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Total Non-Current Liabilities (2016 - 2025)

Palisade Bio (PALI) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 27.59% to $3.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.5 million, a 27.59% increase, with the full-year FY2024 number at $3.2 million, up 20.91% from a year prior.
  • Total Non-Current Liabilities was $3.5 million for Q3 2025 at Palisade Bio, down from $4.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $4.0 million in Q2 2025 to a low of $1.0 million in Q1 2021.
  • A 5-year average of $2.8 million and a median of $2.9 million in 2021 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 380.52% in 2021; the steepest drop was 23.26% in 2021.
  • Palisade Bio's Total Non-Current Liabilities stood at $2.9 million in 2021, then increased by 6.3% to $3.1 million in 2022, then decreased by 13.72% to $2.7 million in 2023, then increased by 20.91% to $3.2 million in 2024, then grew by 7.41% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Total Non-Current Liabilities are $3.5 million (Q3 2025), $4.0 million (Q2 2025), and $2.9 million (Q1 2025).